These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 34245928

  • 1. Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis.
    Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Gouill SL, Béné MC, Chevallier P.
    Transplant Cell Ther; 2021 Oct; 27(10):861.e1-861.e7. PubMed ID: 34245928
    [Abstract] [Full Text] [Related]

  • 2. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A, Raffa E, Wall DA, Schechter T, Ali M, Chopra Y, Kung R, Chiang KY, Krueger J.
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [Abstract] [Full Text] [Related]

  • 3. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Montoro J, Boumendil A, Finel H, Bramanti S, Castagna L, Blaise D, Dominietto A, Kulagin A, Yakoub-Agha I, Tbakhi A, Solano C, Giebel S, Gulbas Z, López Corral L, Pérez-Simón JA, Díez Martín JL, Sanz J, Farina L, Koc Y, Socié G, Arat M, Jurado M, Bermudez A, Labussière-Wallet H, Villalba M, Ciceri F, Martinez C, Nagler A, Sureda A, Glass B.
    Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
    [Abstract] [Full Text] [Related]

  • 4. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation.
    Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N.
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation.
    Yu C, Sun Y, Xu L, Zhang X, Liu K, Jin J, Huang X, Wang Y.
    Transplant Cell Ther; 2021 Aug; 27(8):668.e1-668.e9. PubMed ID: 34052506
    [Abstract] [Full Text] [Related]

  • 6. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.
    Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Le Gouill S, Béné MC, Chevallier P.
    Cancer Med; 2021 Oct; 10(20):7194-7202. PubMed ID: 34547182
    [Abstract] [Full Text] [Related]

  • 7. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation.
    Wada F, Kanda J, Kamijo K, Nishikubo M, Yoshioka S, Ishikawa T, Ueda Y, Akasaka T, Arai Y, Izumi K, Hirata H, Ikeda T, Yonezawa A, Anzai N, Watanabe M, Imada K, Yago K, Tamura N, Itoh M, Masuo Y, Kunitomi A, Takeoka T, Kitano T, Arima N, Hishizawa M, Asagoe K, Kondo T, Takaori-Kondo A.
    Cell Transplant; 2023 Oct; 32():9636897231194497. PubMed ID: 37646153
    [Abstract] [Full Text] [Related]

  • 8. Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation.
    Solomon SR, Bachier-Rodriguez L, Bashey A, Zhang X, Jackson KC, Holland HK, Morris LE, Solh MM.
    Transplant Cell Ther; 2024 Sep; 30(9):903.e1-903.e9. PubMed ID: 38879167
    [Abstract] [Full Text] [Related]

  • 9. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
    Blaise D, Fürst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S, Bouabdallah R, Devillier R, Bramanti S, Lemarie C, Picard C, Chabannon C, Weiller PJ, Faucher C, Mohty B, Vey N, Castagna L.
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
    [Abstract] [Full Text] [Related]

  • 10. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF.
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [Abstract] [Full Text] [Related]

  • 11. Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC.
    Fonseca-Santos M, Bailen R, Lopez-Godino O, Herruzo-Delgado B, Bermudez MA, García-Cadenas I, Huguet-Mas M, Ferra-Coll C, Esquirol A, Cortés-Rodriguez M, Yañez-Sansegundo L, Pascual-Cascon MJ, Heras I, Kwon M, Lopez-Corral L, Grupo Español de Trasplante Hematopoyético y Terapia Celular.
    Transplantation; 2024 Oct 01; 108(10):2134-2143. PubMed ID: 38685204
    [Abstract] [Full Text] [Related]

  • 12. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
    Yu X, Liu L, Xie Z, Dong C, Zhao L, Zhang J, Gu J, Zhu HH.
    Crit Rev Oncol Hematol; 2019 Jan 01; 133():120-128. PubMed ID: 30661648
    [Abstract] [Full Text] [Related]

  • 13. Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
    Solh M, Bashey A, Zhang X, Holland HK, Bachier-Rdriguez L, Morris LE, Solomon SR.
    Transplant Cell Ther; 2024 Jun 01; 30(6):607.e1-607.e8. PubMed ID: 38552844
    [Abstract] [Full Text] [Related]

  • 14. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Fanconi Anemia: Improving Outcomes with Improved Supportive Care in India.
    Uppuluri R, Swaminathan VV, Ramanan KM, Meena S, Varla H, Ramakrishnan B, Jayakumar I, Raj R.
    Biol Blood Marrow Transplant; 2020 Dec 01; 26(12):2292-2298. PubMed ID: 32835780
    [Abstract] [Full Text] [Related]

  • 15. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF, Cheng YF, Xu LP, Zhang XH, Yan CH, Han W, Chen YH, Huang XJ, Wang Y.
    Biol Blood Marrow Transplant; 2020 Sep 01; 26(9):1655-1662. PubMed ID: 32504861
    [Abstract] [Full Text] [Related]

  • 16. Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
    Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S.
    Bone Marrow Transplant; 2024 Jan 01; 59(1):66-75. PubMed ID: 37898725
    [Abstract] [Full Text] [Related]

  • 17. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, Assanelli A, Carrabba MG, Bellio L, Milani R, Lorentino F, Stanghellini MT, De Freitas T, Marktel S, Bernardi M, Corti C, Vago L, Bonini C, Ciceri F, Peccatori J.
    Biol Blood Marrow Transplant; 2015 Aug 01; 21(8):1506-14. PubMed ID: 26001696
    [Abstract] [Full Text] [Related]

  • 18. Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT.
    Luo R, Zhang X, Wang Y, Man Q, Gu W, Tian Z, Wang J.
    Orphanet J Rare Dis; 2022 Dec 02; 17(1):422. PubMed ID: 36461028
    [Abstract] [Full Text] [Related]

  • 19. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO.
    Cancer; 2016 Nov 15; 122(21):3316-3326. PubMed ID: 27404668
    [Abstract] [Full Text] [Related]

  • 20. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.
    Dybko J, Sobczyk-Kruszelnicka M, Makuch S, Agrawal S, Dudek K, Giebel S, Gil L.
    Int J Mol Sci; 2023 Mar 17; 24(6):. PubMed ID: 36982839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.